Effects of 3-month nifedipine treatment on endocrine-metabolic parameters in patients with abdominal obesity and mild hypertension

Journal of Endocrinological Investigation
M MaccarioE Ghigo

Abstract

It is widely accepted that abdominal obesity presents with exaggerated insulin secretion, insulin resistance and a trend toward glucose intolerance. Hypertension is frequently associated to abdominal obesity, and hyperinsulinism could play a role in its pathogenesis. Some studies reported that Ca-antagonists positively influence insulin sensitivity and glucose tolerance in obese patients with normal or elevated blood pressure. However, other studies reported worsening of metabolic balance during treatment with Ca-antagonists in hypertensive non-insulin-dependent diabetes mellitus (NIDDM) patients and in normal subjects. We studied 19 patients with abdominal obesity, mild hypertension and insulin resistance on balanced, mild hypocaloric diet (1400 Kcal), to verify the effects of the Ca-antagonist nifedipine on both basal and oral glucose tolerance test (OGTT)-induced glucose and insulin levels as well as on IGF-I basal and DHEA-S levels and fat mass (FM). To achieve this goal, 10 hypertensive obese subjects (HOB-NIFE, 3 males, 7 females, mean age +/- SD 44.6 +/- 1.7 yr; body mass index (BMI) 37.1 +/- 2.5 Kg/m2, WHR 0.95 +/- 0.02) received 3-month treatment with nifedipine (Adalat Crono 30 Bayer, 1 tab daily) while other 9 hypert...Continue Reading

References

Oct 6, 1978·JAMA : the Journal of the American Medical Association·R StamlerR H Roberts
Jan 1, 1992·Clinical and Experimental Hypertension. Part A, Theory and Practice·E Ferrannini
Jul 1, 1992·American Journal of Hypertension·R L ByynyB Draznin
Jun 1, 1991·Diabetes Care·P P Stein, H R Black
Jan 1, 1991·Journal of Cardiovascular Pharmacology·P ValensiG Perret
Jan 1, 1991·Journal of Cardiovascular Pharmacology·G AndronicoG Cerasola
Oct 1, 1991·The Journal of Clinical Endocrinology and Metabolism·J F Caro
Jan 1, 1991·The Journal of Clinical Endocrinology and Metabolism·J D VeldhuisG Lizarralde
Mar 1, 1989·American Journal of Hypertension·L Landsberg, D R Krieger
Feb 1, 1988·The Journal of Clinical Investigation·K S PolonskyE Van Cauter
Mar 1, 1984·Clinics in Endocrinology and Metabolism·D R Clemmons, J J Van Wyk
Jul 4, 1981·British Medical Journal·S CharlesA E Lambert
Nov 1, 1980·European Journal of Clinical Pharmacology·D GiuglianoM Varricchio
Apr 1, 1995·The Journal of Clinical Endocrinology and Metabolism·M H RasmussenN E Skakkebae
May 1, 1995·Endocrinology·B C VillafuerteL S Phillips
Nov 1, 1995·The Journal of Clinical Endocrinology and Metabolism·D J JakubowiczJ E Nestler
Feb 1, 1995·Endocrine Reviews·J I Jones, D R Clemmons
Oct 1, 1994·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·J E PoulosJ F Caro
Feb 1, 1994·Endocrine Reviews·J P ThissenL E Underwood

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.